Obesity and its related complications are associated with high morbidity and mortality, making it a pathologic condition of global importance 1,2 . Understanding the regulation of the factors that control the storage, mobilization and use of excess energy in adipocytes may lead to the development of potential therapies for obesity and related diseases.
Obesity and its related complications are associated with high morbidity and mortality, making it a pathologic condition of global importance 1, 2 . Understanding the regulation of the factors that control the storage, mobilization and use of excess energy in adipocytes may lead to the development of potential therapies for obesity and related diseases.
In mammals, white adipose tissue (WAT) is the primary energy reservoir and is a major source of metabolic fuel and regulatory adipokines [3] [4] [5] . Brown adipose tissue (BAT) is specialized in energy expenditure and thermogenesis through high fatty acid oxidation in numerous mitochondria and the expression of uncoupling protein 1 (UCP1) 6 .
Transcriptional control of cellular energy metabolic pathways in mammals is achieved by the coordinated action of numerous transcription factors and associated co-regulators 7 , which integrate signals from dietary, metabolic and endocrine pathways to control target gene expression 8 . The co-regulators, which can have either positive (coactivators such as peroxisome proliferative activated receptor-γ, coactivator 1 α (PPARGC1A, also known as PGC1-α) and PGC1-β) or negative (co-repressors such as steroid receptor coactivator-2 (SRC-2) and nuclear receptor interacting protein 1 (NRIP1, also known as RIP140)) gene transcriptional effects on downstream targets 9, 10 , have a crucial role in controlling fat accretion 8 , primarily through the modulation of peroxisome proliferatoractivated receptor-γ (PPAR-γ) activity, the master regulator of adipocyte differentiation and lipid storage 11 .
We identified a new co-regulator of the E2F1-DP1-RB gene transcription complex that is involved in cell-cycle progression. TRIP-Br2 (ref. 12 ) is a member of a family of mammalian transcriptional coregulators comprised of five members 13 , four of which have been shown to modulate E2F-dependent transcriptional activities 12, 14, 15 . Although the role of TRIP-Br2 in adipose tissue is virtually unknown, it has been proposed to recruit transcriptional co-regulators containing plant homeo domain (PHD) zinc finger domains, bromodomains or both 12, 16 , such as p300 and CBP 17 , PCAF and STAF65γ 12, 15, 16 and tripartite motifcontaining 28 (KRIP-1) 12, 18 , to E2F1-DP1 transcription complexes assembled on E2F-responsive promoters. Recent evidence suggests that in addition to its role in cell-cycle regulation, the E2F1-DP1 transcriptional complex regulates adipocyte biology and energy metabolism 19, 20 .
We report that the expression of TRIP-Br2 in adipose tissues is necessary for the development of diet-and age-induced obesity, whereas its ablation enhances adipocyte lipolysis, thermogenesis and oxidative metabolism without ectopic triglyceride storage or an increase in serum nonesterified fatty acid concentrations. To our knowledge, this is the first report of a cell cycle transcriptional co-regulator that modulates fat storage by simultaneously regulating multiple processes, including lipolysis, thermogenesis and oxidative metabolism, leading to enhanced fatty acid turnover in adipocytes. This finding is in contrast to the functions of other known described co-regulators, including PGC1-α, -β, SRC-2 and RIP140, which act by regulating adipocyte lipogenesis and differentiation. The elevated expression of TRIP-Br2 in visceral fat in obese humans and its significant correlation with indices of glucose homeostasis suggests that this transcriptional co-regulator is a new target to treat obesity and its related complications.
RESULTS

Elevated TRIP-Br2 in fat tissue in obesity
Consistent with a potential role in adiposity, TRIP-Br2 gene and protein expression was significantly and selectively upregulated in BAT and epididymal (visceral) and subcutaneous WAT in male C57BL/6J mice fed a high-fat diet (HFD) compared to control mice fed a low-fat diet (LFD) (Fig. 1a and Supplementary Fig. 1a) . Similarly, TRIP-Br2 expression was selectively upregulated in epididymal and subcutaneous adipose tissues from 12-week-old obese (ob/ob) mice ( Fig. 1b  and Supplementary Fig. 1b ) and was downregulated in mice on a calorie-restricted diet (Fig. 1c) .
We also found significantly higher expression of TRIP-Br2 in the visceral (omental) fat from obese individuals, especially those with predominant visceral fat accumulation ( Fig. 1d and Supplementary  Fig. 2a) . TRIP-Br2 expression in visceral fat was significantly correlated with visceral but not subcutaneous fat area ( Fig. 1e and Table 1 ) in both genders ( Supplementary Fig. 2b and Supplementary Tables 1 and 2) independent of the presence of impaired glucose tolerance or diabetes or the treatment modalities of these conditions. The correlation of TRIP-Br2 expression in visceral fat, even after adjustment for visceral fat area, remained significant for fasting plasma insulin concentrations, glucose use during euglycemic-hyperinsulinemic clamp and hemoglobin A1c (HbA1c) concentration, suggesting independent dual roles of TRIP-Br2 in the modulation of adiposity and glucose (g) Body weights of male WT, heterozygous knockout (Het) and knockout (KO) mice on the C57BL/6 (B6) background on either a LFD or a HFD (n = 7-9 mice per group). (h) Body weights of male WT and knockout mice in the original 129Sv founder strain on a HFD (n = 3 mice per group). (i) Representative photographs of male WT, heterozygous and knockout mice as well as fat pads (BAT, subcutaneous and epididymal) and livers of male WT, heterozygous and knockout mice fed with HFD (top). Body length and fat pad and liver weights in absolute amounts from male WT, heterozygous and knockout mice fed with HFD (bottom). (j) Absolute and percentage body composition of male WT and knockout mice fed HFD determined by dual-energy X-ray absorptiometry (DEXA) (n = 6 mice per group). All data are presented as the mean ± s.e.m. *P < 0.05, **P < 0.01, ***P < 0.001 determined by Student's t test. homeostasis ( Table 1 and Supplementary Table 2 ). In both genders, the obesity-adjusted odds of diabetes progressively increased from the first to the fourth quartile of TRIP-Br2 visceral fat expression, with odds ratios (ORs) of 4.6 (95% confidence interval (CI) 1.1-18.6) for the second quartile, 5.1 (95% CI 1.2-21.4) for the third quartile and 9.5 (95% CI 2.2-41.1) for the fourth quartile (Fig. 1f) .
TRIP-Br2 knockout mice resist development of obesity
To elucidate the physiological role of TRIP-Br2, we initiated studies in mice because of the limitations in performing mechanistic studies in human tissues. We investigated gene trap targeted TRIP-Br2 knockout male mice on the original 129Sv founder background 21 and the C57BL/6J background and used the latter group for our studies. We confirmed successful ablation by the virtual absence of TRIP-Br2 gene and protein expression, whereas the expression of TRIP-Br1, TRIP-Br3 and TRIP-Br4 remained unaltered (Supplementary Fig. 3 ).
To potentially unmask the knockout phenotype, we placed the wildtype (WT), heterozygous knockout and knockout mice on either a LFD (10% fat by kcal) or a HFD (60% fat by kcal) for 12 weeks. The knockout mice on the LFD showed a trend to reduce (~10%; P = 0.05) their body weights (Fig. 1g) . However, on the HFD, the knockout mice were significantly leaner (Fig. 1g) . At the end of the HFD, the knockout mice showed little change in their body weights and had similar weights to the WT mice on the LFD (P = 0.92) (Fig. 1g) . We also observed a protection against weight gain in the knockout mice even when maintained on the 129Sv background, which is known to resist diet-induced obesity 22 (Fig. 1h) . Notably, knocking out TRIP-Br2 also protected the mice from age-induced obesity (WT, 51.2 ± 2.7 g (mean ± s.e.m.); heterozygous, 47.6 ± 3.9 g; knockout, 43.9 ± 1.9 g; WT compared to knockout, P < 0.01). Food intake ( Supplementary Fig. 4a ), gene expression of appetite-regulating peptides in the hypothalamus (Supplementary Fig. 4b ) and the ability of the intestine to absorb fat 23 were similar between groups (Supplementary Fig. 5 ).
The lower body weight of TRIP-Br2 knockout mice was accounted for largely by a reduction in WAT weight ( Fig. 1i and Supplementary  Fig. 6 ) without an alteration in lean body mass or body length in HFD-fed mice (Fig. 1i,j) . On the LFD, the lack of a significant decrease in body weight in the knockout mice (Fig. 1g) was probably masked by an increase in their lean body mass despite a significant (P < 0.05) reduction in the percentage of fat mass ( Supplementary  Fig. 7 ), indicating protection from diet-and age-induced obesity as a result primarily of lower fat mass.
TRIP-Br2 knockout mice resist detrimental effects of obesity TRIP-Br2 knockout mice fed a HFD showed improved glucose tolerance and insulin sensitivity (Fig. 2a) and lower fasting glucose and insulin concentrations (Fig. 2b) . Further, the fed serum adiponectin concentrations 24 were significantly higher in knockout mice on the HFD (Fig. 2b) . Consistently, adiponectin mRNA levels were higher in the HFD knockout mice compared to WT mice (Fig. 2b) . Increased adipocyte volume and number are positively correlated with leptin production 25 . The HFD-induced 4.5-fold increase in serum leptin concentration in WT mice (Fig. 2b) was also reflected by higher adipose leptin mRNA levels, whereas serum leptin concentrations remained low in the HFD-fed knockout mice. TRIP-Br2 knockout mice had significantly lower fed and fasting serum cholesterol concentrations and a trend to decrease triglyceride concentrations on the HFD (Fig. 2b and Supplementary Fig. 8a ). Despite the increased lipolysis in TRIP-Br2 knockout mice (discussed below), serum nonesterified fatty acid (NEFA) concentrations remained in the normal range in knockout mice on the HFD diet (Supplementary Fig. 8a ).
In contrast, the TRIP-Br2 knockout mice fed a LFD showed a trend toward improved insulin sensitivity and a mild metabolic phenotype, probably as a result of an insignificant reduction in their body weights ( Fig. 1g and Supplementary Figs. 8a,b and 9) . To confirm the effect of TRIP-Br2 knockout on insulin sensitivity, we stimulated LFD-fed mice in vivo or differentiated adipocytes overexpressing TRIP-Br2 in vitro with insulin and found that expression of proteins in the insulin signaling pathway were not significantly different between the two groups in the liver and muscle (Supplementary Fig. 10 ), and we found this same result in the differentiated adipocytes ( Supplementary Fig. 11 ).
Chronic exposure of mice to HFD causes fatty liver (steatosis) 26 . Feeding a HFD increased liver mass only in the WT mice (Fig. 1g) , whereas in the knockout mice, the livers had smaller lipid-containing vacuoles and reduced triglyceride content (Fig. 2c) .
Obesity is associated with an increase in macrophage infiltration in visceral adipose tissue 27, 28 . Adipose tissues from TRIP-Br2 knockout mice on the HFD had 57% less adipose tissue macrophage infiltration (Fig. 2d) . Consistently, the mRNA expression of two macrophage markers, F4/80 and monocyte chemoattractant protein-1 (MCP-1), was significantly lower in WAT of TRIP-Br2 knockout mice (Fig. 2d) . These data suggest that TRIP-Br2 is one factor that mediates the detrimental effects of HFD-induced obesity, such as glucose intolerance, insulin resistance, changes in adiponectin, leptin and serum lipid concentrations, hepatic steatosis and adipose tissue inflammation.
Reduced adipocyte size in TRIP-Br2 knockout mice A decrease in adipose tissue mass could result from a reduction in adipocyte size, a reduction in adipocyte number as a result of impaired differentiation or both 29 . The mRNA levels of adipogenic transcription factors 30 , as well as of late markers of adipocyte differentiation, were not significantly different in WAT between groups, suggesting normal adipocyte differentiation in both fat depots ( Supplementary  Fig. 12a ). In addition, we found no significant differences in morphology or lipid accumulation or in the mRNA expression of early and late adipogenesis markers in TRIP-Br2-overexpressing or TRIP-Br2 knockdown 3T3-L1 cells differentiated in vitro ( Supplementary  Fig. 12b,c) . These results suggest that TRIP-Br2 is not important for adipocyte differentiation. A downregulation of endogenous TRIP-Br2 expression during the differentiation of WT adipocytes ( Supplementary Fig. 13 ) argues for a putative repressor role in mature adipocytes. However, histological analyses revealed a significantly greater frequency of small adipocytes and a lower frequency of midsized and large adipocytes in epididymal WAT from the knockout mice on HFD (Fig. 2e,f and Supplementary Fig. 14) . Thus, TRIP-Br2 ablation leads to adipocyte hypotrophy as a result of lower triglyceride accumulation ( Fig. 2f) and smaller adipocyte size rather than impaired adipocyte differentiation.
Absence of TRIP-Br2 increases fat lipolysis
We next examined whether the marked decrease in adipocyte cell size in the knockout mice is caused by alterations in lipolysis or lipogenesis. Although we found no differences in either the rate of lipogenesis or the gene expression of lipogenesis markers 31 in epididymal adipocytes between groups ( Supplementary Fig. 15 ), β-adrenergic agonist (isoproterenol)-stimulated lipolysis was significantly higher in adipocytes from TRIP-Br2 knockout mice fed either LFD or HFD Quantification of F4/80 + crown-like structures in epididymal fat from male WT and knockout mice fed HFD (middle). Immunofluorescence images were used to quantify the percentage of crown-like structures. Three to five low-power fields were analyzed for four mice per genotype (>1,000 adipocytes per genotype). ATM, adipose tissue macrophage. F4/80 and MCP-1 mRNA in subcutaneous (SubQ) and epididymal fat from male WT, heterozygous and knockout mice fed with HFD (n = 7-9 mice per group) (right). (e) Representative images of H&E-stained sections of subcutaneous and epididymal fat and BAT from male WT and knockout mice fed HFD (left). Scale bar, 100 µm. Brown adipocyte numbers in WT and knockout BAT (right). (f) Representative confocal images of caveolin-stained epididymal adipose tissue (left) and the frequency distribution of adipocyte cell size in epididymal adipose tissue from WT and knockout mice fed with HFD (middle). Scale bar, 100 µm. Triglyceride content of epididymal and subcutaneous fat from male WT and knockout mice fed HFD (n = 5 mice per group) (right). All data are presented as the mean ± s.e.m. *P < 0.05, **P < 0.01, ***P < 0.001 determined by Student's t test.
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( Fig. 3a and Supplementary Fig. 16 ). Further, whereas HFD feeding blunted the isoproterenol-stimulated lipolytic response of WT adipocytes, the adipocytes from TRIP-Br2 knockout mice fed either diet remained sensitive (Supplementary Fig. 16 ). We confirmed this finding by lipolysis assay in in vitro-differentiated TRIP-Br2 knockdown or TRIP-Br2-overexpressing 3T3-L1 cells (Fig. 3b) . To further confirm the lipolysis changes in vitro or ex vivo, we measured the lipolysis rate in vivo by either intraperitoneal injection of the CL316342 compound 32 , a β3-adrenergic agonist, or the heavy-water labeling technique 33, 34 . The two approaches independently confirmed a significant increase in the in vivo lipolysis rate in the TRIP-Br2 knockout mice (Fig. 3c,d ).
Analyses of key lipolytic genes in the epididymal fat of TRIP-Br2 knockout mice on either diet revealed unchanged concentrations of adipose triglyceride lipase (ATGL) 35 or its co-regulators, including abhydrolase domain containing 5 (ABHD5, also known as CGI-58) and G0/G1 switch 2 (G0S2) (Fig. 3e,f, Supplementary Figs. 17 and  18) ; however, we did find a significant increase in the concentration of another key lipolytic enzyme, hormone sensitive lipase (HSL), at both the mRNA and protein levels 36 (Fig. 3e,f and Supplementary Fig. 19 ), but not an increase in one of the HSL regulators, perilipin A. Notably, we found an increase in Plin1 (encoding perilipin A) gene expression (Supplementary Fig. 17 ) but not in the protein concentration of perilipin A (Supplementary Fig. 18 ) in the epididymal fat from the HFD-fed knockout mice. We also found a significant increase in the mRNA and protein expression of Adrb3 in all adipose depots from HFD-fed knockout mice (Fig. 3e,f) .
Stimulation of Adrb3 signaling phosphorylates HSL and increases HSL-mediated lipolysis, leading to reduced fat mass 37 . Consistently, we found an increase in HSL phosphorylation in TRIP-Br2 knockout mice (Fig. 3f) . In the knockout mice fed a LFD, we found a significant (P < 0.05) increase in Adrb3 and HSL mRNA levels in the epididymal WAT (Supplementary Fig. 19 ). Consistent with the in vivo data, HSL and Adr3b gene and protein expressions were downregulated in differentiated 3T3-L1 adipocytes overexpressing TRIP-Br2, and we found that ATGL concentrations were unchanged (Fig. 3g) .
Further, treatment of TRIP-Br2 knockout adipocytes with an HSLspecific inhibitor, 4-isopropyl-3-methyl-2-[1-(3-(S)-methyl-piperidin-1-yl)-methanoyl]-2H-isoxazol-5-one (BAY) 38 , completely prevented the increase in isoproterenol-stimulated lipolysis in TRIP-Br2 knockout adipocytes (Fig. 3h) , confirming the role of HSL as the major lipolytic enzyme regulated by TRIP-Br2 in the adipocyte.
To dissect the relative importance of Adr3b and HSL in the TRIP-Br2 knockout adipocytes, we stimulated isolated primary adipocytes with isoproterenol, forskolin or isobutylmethylxanthine (IBMX) to either activate Adr3b or increase the concentration of cyclic AMP to indirectly enhance HSL enzyme activity. Notably, isoproterenol-stimulated lipolysis tended to be consistently higher compared to that resulting from stimulation with forskolin or IBMX (Fig. 3i) , suggesting that the primary site for action is an increase in Adr3b signaling in the TRIP-Br2 knockout adipocyte. We confirmed this finding in the differentiated TRIP-Br2 knockdown 3T3-L1 cell line (Fig. 3i) .
These results suggest that increased lipolysis in adipocytes and reduced adiposity in the knockout mice is mediated by specific regulation of Adr3b and HSL.
Enhanced thermogenesis in TRIP-Br2 knockout mice Reduction in adipose tissue mass without alterations in food intake ( Supplementary Fig. 4a ) suggested a potential increase in energy expenditure in the knockout mice. Indeed, measurement of oxygen consumption (VO 2 ) rates over 48 h (including light and dark phases) revealed ~20% higher consumption in the knockout mice (Fig. 4a) , which could not be attributed to changes in activity ( Supplementary  Fig. 20a ). The rate of carbon dioxide elimination (VCO 2 ) was unchanged (Supplementary Fig. 20b) . Consistent with the higher VO 2 , the knockout mice generated more heat ( Supplementary  Fig. 20c) , with a ~0.7 °C higher basal core body temperature and a higher body temperature for up to 3 h even in a cold environment (4 °C) (Fig. 4b) , suggesting enhanced adaptive thermogenesis. The generally lower respiratory quotient (VCO 2 /VO 2 ) in the TRIP-Br2 knockout mice indicated higher fat use (Supplementary Fig. 20d ).
These data indicating increased thermogenesis in the TRIP-Br2 knockout mice prompted us to examine BAT. Notably, although we did not detect significant alterations in the gross appearance or weight of interscapular BAT in the knockout mice, we found a significant increase in the number of smaller adipocytes associated with smaller lipid droplets (Figs. 1i and 2e) . These results indicate that an absence of TRIP-Br2 increases thermogenesis, in part, because of an increase in brown adipocyte number.
Consistent with the increase in thermogenesis and VO 2 in the knockout mice, we found an upregulation of gene expression for UCP1, PGC1A, ECH1 (peroxisomal enoyl coenzyme A hydratase 1), Cyc1 (cytochrome C) and Cox8b (cytochrome c oxidase subunit VIIIb), which are genes involved in thermogenesis, oxidative metabolism and mitochondrial biogenesis ( Fig. 4c and Supplementary Fig. 21) . Further, examination of BAT in mice exposed to a cold environment revealed a significant upregulation in the expression of HSL and Adrb3 (Fig. 4c) , consistent with observations under ambient conditions (Fig. 3e) . The cold-exposed BAT from the knockout mice also showed a significant upregulation of genes involved in thermogenesis and both mitochondrial and peroxisomal fatty acid oxidation (Fig. 4c) . Thus, ablation of TRIP-Br2 in brown adipocytes leads to upregulation of Adrb3 expression and genes essential for adaptive thermogenesis and oxidative metabolism. Considering that Adrb3 signaling regulates thermogenesis and fatty acid oxidation pathways 39 , or with knockdown of TRIP-Br2 by shRNA (KD) and with or without isoproterenol stimulation (n = 3 mice per group). All data are presented as the mean ± s.e.m. *P < 0.05, **P < 0.01 (compared to sham WT (f) or control basal (i)), # P < 0.05 (compared to denervated WT (f), ### P < 0.001 (compared to control stimulated (i)), + P < 0.05, ++ P < 0.01 (compared to sham knockout (f)) determined by Student's t test.
the significant upregulation of Adrb3 expression by cold exposure could potentially upregulate the genes involved in thermogenesis and fatty acid oxidation observed in BAT in the knockout mice. These data were further supported by our observation that the BAT in TRIP-Br2 knockout mice has a significantly higher oxygen consumption rate (OCR) (Fig. 4d) and an increased ratio of OCR to extracellular acidification rate (ECAR) (Fig. 4e) , suggesting that the BAT lacking TRIP-Br2 has enhanced oxidative metabolism compared to BAT in WT control mice. To further determine its role, we denervated the BAT and found that this manipulation only partially reversed the TRIP-Br2 obesity-resistant phenotype (Fig. 4f) , suggesting contributions from other tissues. In epididymal WAT of TRIP-Br2 knockout mice, we detected an elevated expression of genes ( Fig. 4g and Supplementary Fig. 22 ) involved in promoting fatty acid oxidation. Consistently, the basal and isoproterenol-stimulated fatty acid oxidations were enhanced in the isolated primary TRIP-Br2 knockout adipocytes (Fig. 4h) . We confirmed this finding in vitro, where the basal and isoproterenolstimulated fatty acid oxidation rates were reduced in the differentiated 3T3-L1 adipocytes overexpressing TRIP-Br2 and, conversely, were enhanced in adipocytes with TRIP-Br2 knockdown (Fig. 4i) . The upregulation of UCP1 and oxidative metabolism genes is expected to result in the uncoupling of fatty acid oxidation and the enhancement of in situ fatty acid use, which provides a plausible explanation for the lack of increase in serum NEFA concentration despite an elevated lipolytic activity in the WAT of TRIP-Br2 knockout mice. This hypothesis is further supported by unchanged fatty acid oxidation in TRIP-Br2 knockout skeletal muscle ( Supplementary  Fig. 23 ), a tissue known to be a major organ that utilizes circulating free fatty acids. These findings suggest a model in which normal TRIP-Br2 expression is permissive for the development of obesity and its related complications through its effect on reducing energy expenditure and fat oxidation in adipocytes by downregulating the expression of key proteins involved in adipocyte lipolysis, thermogenesis and oxidative metabolism (Fig. 5) .
TRIP-Br2 co-regulates HSL and Adrb3 transcription
We next used in silico sequence analysis to identify putative E2F consensus binding sites in the promoter sequences of mouse HSL (HSL) and Adrb3 (Supplementary Fig. 24 ) that were conserved between the murine and human orthologs. Co-transfection of NIH-3T3 cells with expression constructs of E2F1, E2F4, DP1 or TRIP-Br2 with luciferase reporter constructs (pGL3) driven by the promoters of the HSL or Adrb3 genes revealed that overexpression of either the E2F1-DP1 or the E2F4-DP1 transcriptional complex stimulates both HSL and Adrb3 promoter-driven luciferase expression, whereas the coexpression of TRIP-Br2 consistently repressed both promoter activities ( Fig. 5a and Supplementary Fig. 25 ). We confirmed these results by partial deletion and site-directed mutagenesis of putative E2F consensus binding sites. Our results show that the first two E2F sites in the HSL promoter (−445 bp and −240 bp) and both of the E2F sites in the Adrb3 promoter are responsive to both E2F1-DP1-and E2F4-DP1-mediated transcriptional activation and TRIPBr2 co-regulator-mediated transcriptional inhibition ( Fig. 5a and Supplementary Fig. 25 ).
To confirm the binding of TRIP-Br2 on the HSL and Adrb3 promoters in vivo, we performed chromatin immunoprecipitation (ChIP) in differentiated 3T3-L1 adipocytes stably expressing TRIP-Br2-Flag or empty vector control. Fragments of HSL and Adrb3 promoters containing the E2F binding sites were enriched in the genomic DNA immunoprecipitated from TRIP-Br2-FLAG-overexpressing adipocytes using an antibody to Flag and detected by quantitative RT-PCR (Fig. 5b) . Conversely, neither glyceraldehyde-3-phosphate dehydrogenase (GAPDH; negative control) nor the respective promoter regions lacking the E2F sites could be detected in the immunoprecipitated genomic DNA samples (Supplementary Fig. 26) . We further confirmed the luciferase promoter analyses demonstrating co-repressor activity of TRIP-Br2 on the transcriptional readouts of the HSL and Adrb3 promoters by showing decreased RNA polymerase II binding at the HSL and Adrb3 promoters in TRIP-Br2-Flagoverexpressing differentiated adipocytes (Fig. 5b) .
To confirm the functionality of the E2F binding sites on the HSL promoter, we mutagenized the first two endogenous E2F binding sites on the HSL promoter in 3T3-L1 cells using a newly developed genome modification technique, Transcription Activator-Like Effector Nucleases (TALENs) 40 . Mutagenesis of the HSL promoter E2F binding sites abolished the enhanced isoproterenol-stimulated lipolysis in the differentiated TRIP-Br2 knockdown 3T3-L1 adipocytes (Fig. 5c) , confirming the functionality and crucial role of TRIP-Br2-E2F regulation on HSL in the adipocyte.
Taken together, these data suggest that TRIP-Br2 is recruited as a co-repressor to E2F1-DP1 or E2F4-DP1 complexes assembled on E2F consensus binding sites in the HSL and Adrb3 promoters.
DISCUSSION
Over the past several decades, adipocytes have been the target of intense investigation because of the emergence of obesity as a serious public health problem. Furthermore, adipocytes have been shown to be crucial integrators of various physiological pathways regulating whole-body glucose and energy homeostasis 3 . Identifying points of regulatory convergence that can serve as therapeutic targets to improve glucose and energy homeostasis is therefore of great necessity.
Transcriptional co-regulators have been clearly identified as having dominant roles in metabolism and energy homeostasis 8, 41 . Despite the identification of numerous coactivators and co-repressors (for example, PGC1 and RIP140), most of the co-regulators have shown prominent roles in fat accretion and adipocyte differentiation, primarily through the modulation of the master regulator, the PPAR-γ transcription factor. In this study we identify a new transcriptional co-regulator, TRIP-Br2, for the regulation of adiposity and energy metabolism, and we also report a link between cell-cycle regulators (the E2F family) and energy homeostasis. To our knowledge, this is the first report of a cell cycle transcriptional co-regulator capable of modulating fat storage by simultaneous regulation of multiple processes, including lipolysis, thermogenesis and oxidative metabolism, leading to enhanced fatty acid turnover in adipocytes. TRIP-Br2 seems to be functionally different from the other previously described transcriptional co-regulators, which regulate adipocyte lipogenesis and differentiation. Our studies suggest that TRIP-Br2 mediates this metabolic phenotype, in part, through transcriptional regulation of HSL and Adrb3 expression.
We found that β-adrenergic agonist-stimulated lipolysis was markedly increased in vivo in TRIP-Br2 knockout mice as well as ex vivo in isolated primary adipocytes from TRIP-Br2 knockout mice. Consistently, expression of HSL and Adrb3 were both significantly enhanced in adipose tissues from the knockout mice, suggesting that the enhanced stimulated lipolysis is the result of an increase in the expression of key proteins in the β-adrenergic-regulated lipolytic pathway. However, because of technical limitations in accurately monitoring the rate of lipolysis by the release of fatty acids or glycerol, we are unable to rule out the effects of TRIP-Br2 knockout on fatty acid re-esterification.
The enhanced lipolysis is consistent with the observation of smaller adipocytes and reduced lipid accumulation in WAT and BAT of the TRIP-Br2 knockout mice on a HFD. This finding is consistent with other studies reporting a smaller fat pad and adipocyte size secondary to increased lipolytic activity in adipose-specific desnutrin (also known as ATGL) overexpressors 34 and adipose-specific phospholipase A2 (AdPLA) knockout 42 mice. Lipolysis in adipocytes is under tight hormonal regulation and is dependent on nutritional status. For example, during fasting, increased concentrations of catecholamines bind to β-adrenergic receptors and promote the activation of HSL, whereas in the fed state, lipolysis is inhibited by insulin. Our data suggest that an absence of TRIP-Br2 enhances fasting-stimulated β-adrenergic-regulated lipolytic activities.
However, it is evident that enhanced lipolysis alone may not be adequate to account for all the observed phenotypes in the TRIP-Br2 knockout mice, as demonstrated by a study in which HSL overexpression did not induce a lean phenotype in mice fed a HFD 43 . However, unlike the simultaneous upregulation of both HSL and Adrb3 caused by ablation of TRIP-Br2, Adrb3 was not simultaneously overexpressed in the HSL overexpression study. We found no significant increase in serum NEFA concentration in the TRIP-Br2 knockout mice. We hypothesize that the lack of an increase in serum NEFA concentration despite enhanced lipolysis in TRIP-Br2 knockout mice reflects the use of alternative mechanisms that allow the use of excess fat and fatty acids in the mutant mice. Indeed, we found enhanced fatty acid oxidation in isolated primary adipocytes from the TRIP-Br2 knockout mice and in differentiated 3T3-L1 adipocytes with reduced expression of TRIP-Br2. In addition, the finding of increased oxygen consumption and heat production in the knockout mice also indicates an increase in energy expenditure in vivo. The higher core body temperature and superior cold tolerance indicate an increase in adaptive thermogenesis in the knockout mice. This energy expenditure phenotype is consistent with a substantial upregulation in the expression of genes that regulate thermogenesis and mitochondrial and peroxisomal fatty acid oxidation in both WAT and BAT. Further, ectopic expression of UCP1 in WAT has been reported to cause resistance to diet-induced obesity with increased fatty acid oxidation in adipocytes 44 . As peroxisomal fatty acid oxidation is associated with efficient uncoupling 34, 45 , the elevated concentrations of peroxisomal fatty acid oxidation in TRIPBr2 knockout mice are consistent with a switch from ATP production to heat generation in WAT and BAT. In BAT, cold-induced PGC1-α expression has been reported to regulate thermogenesis by promoting mitochondrial respiration and uncoupling electron transfer from ATP synthesis through the induction of UCP1 (refs. 46,47) . In our study we found that numerous genes involved in thermogenesis and fatty acid oxidation were upregulated in cold-induced BAT in the npg knockout mice. Together, our findings indicate that fatty acids liberated by enhanced lipolysis could be used potentially as fuel by the increased fatty acid oxidation and thermogenesis that together contribute to a leaner phenotype in the TRIP-Br2 knockout mice.
Our data demonstrate that despite enhanced lipolysis in TRIP-Br2 knockout mice, coordinate upregulation of fatty acid oxidation and thermogenesis in both WAT and BAT leads to enhanced in situ fatty acid use, as well as the absence of increased circulating NEFA concentrations and ectopic fat accumulation in metabolic organs such as liver, a finding that is clearly observed in WT mice fed with a HFD. This hypothesis is further supported by a recent observation that an increase in lipolysis and release of free fatty acids by the adipocytes during weight loss or in fasting mice leads to an increase in inflammation in adipose tissues 48 . In the TRIP-Br2 knockout mice, despite a notable increase in lipolysis, we observed markedly less inflammation in the adipose tissues, consistent with our hypothesis that the free fatty acid generated from enhanced lipolysis is potentially used in situ in the adipocyte rather than released into the circulation.
Cell-cycle regulators have been increasingly implicated in the control of metabolism 49 . Our data provide evidence that both E2F1-DP1 and E2F4-DP1 form transcription complexes with TRIP-Br2 to regulate the β3-adrenergic-regulated lipolytic and mitochondrial β-oxidative pathways. This is in contrast to a previous report that E2F1 and E2F4 modulation of PPAR-γ transcription regulates adipocyte differentiation 19, 20 .
The resistance to HFD-induced obesity and lean phenotype shown by TRIP-Br2 knockout mice and the selective elevation of TRIP-Br2 in visceral fat in obese humans makes it an attractive therapeutic target for the treatment of obesity and obesity-related metabolic diseases.
METHODS
Methods and any associated references are available in the online version of the paper. 
ONLINE METHODS
Animals. The creation of the original TRIP-Br2 knockout outbred mouse strain in the 129Sv background and the generation of a TRIP-Br2 inbred mouse strain on a C57BL/6 background by over ten generations of backcrossing have been previously reported 21 . Mice were housed in pathogen-free facilities and maintained on a 12-h light, 12-h dark cycle at the Foster Biomedical Research Laboratory of Brandeis University in Waltham, MA. All protocols were approved by the Institutional Animal Care and Use Committee of the Joslin Diabetes Center and Brandeis University and were in accordance with US National Institutes of Health guidelines.
Subjects. Paired samples of visceral and subcutaneous adipose tissue were obtained from 178 men (n = 92) and women (n = 86) of European ancestry who underwent abdominal surgery as described in detail elsewhere 50 . The age of the subjects ranged from 16 to 82 years, and all had a BMI between 20.8 and 54.1 kg m -2 . In these subjects, abdominal visceral and subcutaneous fat area was calculated using abdominal magnetic resonance imaging scans or computed tomography scans at the level of L4-L5. Percentage body fat was measured by DEXA. Individuals assigned to all three cohorts (lean, BMI < 25; or visceral obesity, visceral or subcutaneous fat area >0.4) fulfilled the following inclusion criteria: (i) absence of any acute or chronic inflammatory disease as determined by a leukocyte count >7,000 Gpt l -1 , C-reactive protein >5.0 mg dl -1 or clinical signs of infection; (ii) undetectable antibodies against glutamic acid decarboxylase (GAD); (iii) no medical history of hypertension (that is, systolic blood pressure <140 mm Hg and diastolic blood pressure <85 mm Hg); (iv) no clinical evidence of either cardiovascular or peripheral artery disease; (v) no thyroid dysfunction; (vi) no alcohol or drug abuse; and (vii) no pregnancy. All subjects had a stable weight with fluctuations smaller than 2% of the body weight for at least 3 months before surgery. Normal glucose tolerance was defined as fasting plasma glucose <6.0 mmol l -1 and a 120-min OGTT plasma glucose <7.8 mmol l -1 . Impaired glucose tolerance was defined as fasting plasma glucose <6.0 mmol l -1 and a 120-min OGTT plasma glucose >7.8 mmol l -1 and <11.1 mmol l -1 . Type 2 diabetes was defined as fasting plasma glucose >7.0 mmol l -1 , a 120-min OGTT glucose >11.1 mmol l -1 or both. The study was approved by the ethics committee of the University of Leipzig. All subjects gave written informed consent before taking part in the study.
Fasting plasma insulin concentration was measured with an enzyme immunometric assay for the IMMULITE automated analyzer (Diagnostic Products Corporation). Plasma leptin concentrations were assessed by radioimmunoassay (Millipore). The OGTT was performed after an overnight fast with 75 g standardized glucose solution (Glucodex Solution 75 g, Merieux), and insulin sensitivity was assessed with the euglycemic-hyperinsulinemic clamp method as described 51 .
TRIP-Br2 mRNA expression in human visceral and subcutaneous adipose tissue. Human TRIP-Br2 mRNA expression was measured by quantitative realtime RT-PCR in a fluorescent temperature cycler, and fluorescence was detected on an ABI PRISM 7000 sequence detector (Applied Biosystems). Total RNA was isolated from paired subcutaneous and omental adipose tissue samples using TRIzol (Life Technologies), and 1 µg RNA was reverse transcribed with standard reagents (Life Technologies). TRIP-Br2 mRNA expression was determined by a premixed assay on demand: Hs00207372_m1 SERTA domain containing 2 (Applied Biosystems). Samples were incubated in the ABI PRISM 7000 sequence detector for an initial denaturation at 95 °C for 10 min, followed by 40 PCR cycles, each cycle consisting of 95 °C for 15 s, 60 °C for 1 min and 72 °C for 1 min. TRIP-Br2 mRNA expression was calculated relative to the mRNA expression of HPRT1 determined by a premixed assay on demand for human HPRT1 (Applied Biosystems). Amplification of specific transcripts was confirmed by melting curve profiles (cooling the sample to 68 °C and heating slowly to 95 °C with measurement of fluorescence) at the end of each PCR. The specificity of the PCR was further verified by subjecting the amplification products to agarose gel electrophoresis.
Statistical analyses for human subject data. All analyses were conducted with the two genders considered together as well as separately. TRIP-Br2 expression in subcutaneous and visceral fat was compared between lean and obese subjects by t tests. The unadjusted correlation between TRIP-Br2 expression and metabolic parameters was evaluated by Pearson's correlation coefficients. Adjusted correlation coefficients were derived from partial r 2 values obtained from analysis of covariance models that included each of the metabolic parameters and the visceral fat area as predictors of TRIP-Br2 expression. The associations between the quartiles of TRIP-Br2 visceral fat expression and risk of type 2 diabetes were evaluated by logistic regression with and without adjustment for visceral and subcutaneous fat areas and expressed as ORs and their 95% CIs.
Body weight study. For diet-induced obesity, all male mice were fed a chow diet (21.6% fat, 23% protein and 55.4% carbohydrate by kcal; #5020, LabDiet) until 6 weeks of age. Subsequently, mice were assigned randomly to either a LFD (10% fat, 20% protein and 70% carbohydrate by kcal; D12450B, Research Diets) or an HFD (60% fat, 20% protein and 20% carbohydrate by kcal; D12492, Research Diets) until the end of the experimental protocol. Body weight was measured weekly until 18 weeks of age.
Adipocyte size determination. Adipocyte cross-sectional areas from caveolinstained (BD Biosciences) adipose tissue images (150-200 adipocytes per mouse and three mice per genotype) were calculated using CellProfiler image analysis software (Broad Institute, http://www.cellprofiler.org/) 52, 53 .
Fatty acid oxidation. Differentiated 3T3-L1 cells were treated with either vehicle or isoproterenol for 1 h. Cells were then washed and incubated with assay medium containing 2% fatty acid-free BSA, 0.30 mM l-carnitine and 3 H-palmitic acid (3 µCi per well) in low-glucose DMEM medium for 1 h. Fatty acid oxidation was determined by measuring 3 H 2 O production as previously described and normalized with total cellular protein 45 .
Isolated white and brown adipocytes were used to determine fatty acid oxidation by measuring 14 CO 2 production from [U-14 C] palmitic acid (0.2 µCi per ml) after incubation for 1 h at 37 °C with gentle shaking as previously described before being normalized with total lipid content 54 .
Genomic mutagenesis. TALEN plasmid DNA was designed, synthesized and tested by Cellectis Bioresearch. The exchange and integration matrix harboring the mutation was synthesized by GenScript. 3T3-L1 preadipocytes at 50-60% confluency were transfected with 1 µg of each TALEN plasmid and exchange matrix using Lipofectamine 2000 (Invitrogen). Twenty-four hours after transfection, cells were trypsinized and selected using puromycin. Colonies were then picked and expanded before screening with PCR and confirmed with sequencing.
Adipose tissue oxygen consumption and extracellular acidification. OCR and ECAR values were determined in mouse BAT using a modified protocol 55 . Briefly, freshly isolated BAT from WT and TRIP-Br2 knockout mice (n = 5 mice per genotype) were rinsed with unbuffered Krebs Henseleit buffer (KHB) medium containing 111 mM NaCl, 4.7 mM KCl, 2 mM MgSO 4 , 1.2 mM Na 2 HPO 4 , 0.5 mM carnitine and 2.5 mM glucose. Adipose tissue was cut into small pieces and rinsed with KHB medium, and 10 mg of tissue was placed in each well of an XF24-well Islet Flux plate (Seahorse Bioscience). Then, 450 µl of KHB medium was added to each well, and samples were analyzed in an XF24 Extracellular Flux Analyzer (Seahorse Bioscience) at 37 °C (ref. 56) . The XF24 Analyzer mixed the media in each well three times for 2 min before measurements to allow the oxygen partial pressure to equilibrate. Basal OCR and ECAR were measured in all wells three times. Five tissue replicates from five mice per genotype were analyzed in independent experiments, and results were normalized to tissue weight.
Ex vivo lipolysis and lipogenesis. Isolated adipocytes were incubated with or without increasing doses of isoproterenol (10 -6 -10 -9 M), isoproterenol (5 µM), forskolin (20 µM) or IBMX (0.2 µM) for 90 min. Extracellular glycerol release was extracted and measured using Free Glycerol Reagent (Sigma) as an indicator of lipolysis 57 . For the assessment of lipogenesis, isolated adipocytes were incubated with [ 14 C] deoxyglucose in the presence or absence of increasing concentrations of insulin (0.1-100 nM) for 90 min. Incorporated radiolabeled glucose was extracted and measured using liquid scintillation counting 58 . npg
